PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier

JOURNAL OF CONTROLLED RELEASE

卷:211

Article

Fornaguera, C.^1,2  Dols-Perez, A.^1,2  Caldero, G.^1,2  Garcia-Celma, M. J.^2,3  Camarasa, J.⁴  Solans, C.^1,2 

[1] CSIC, IQAC, Inst Adv Chem Catalonia, Barcelona, Spain

[2] CIBER BBN, Barcelona, Spain

[3] Univ Barcelona, Dept Pharm & Pharmaceut Technol, E-08028 Barcelona, Spain

[4] Univ Barcelona, Pharmacol Sect, Dept Pharmacol & Therapeut Chem, E-08028 Barcelona, Spain

关键词: Nano-emulsions;    Polymeric nanoparticles;    Loperamide;    Blood-brain barrier;    Active targeting;   

DOI  :  10.1016/j.jconrel.2015.06.002

来源: Elsevier

【 摘 要 】

Neurodegenerative diseases have an increased prevalence and incidence nowadays, mainly due to aging of the population. In addition, current treatments lack efficacy, mostly due to the presence of the blood-brain barrier (BBB) that limits the penetration of the drugs to the central nervous system. Therefore, novel drug delivery systems are required. Polymeric nanoparticles have been reported to be appropriate for this purpose. Specifically, the use of poly-(lactic-co-glycolic acid) (PLGA) seems to be advantageous due to its biocompatibility and biodegradability that ensure safe therapies. In this work, a novel approximation to develop loperamide-loaded nanoparticles is presented: their preparation by nano-emulsion templating using a low-energy method (the phase inversion composition, PIC, method). This nano-emulsification approach is a simple and very versatile technology, which allows a precise size control and it can be performed at mild process conditions. Drug-loaded PLGA nanoparticles were obtained using safe components by solvent evaporation of template nano-emulsions. Characterization of PLGA nanoparticles was performed, together with the study of the BBB crossing. The in vivo results of measuring the analgesic effect using the hot-plate test evidenced that the designed PLGA loperamide-loaded nanoparticles are able to efficiently cross the BBB, with high crossing efficiencies when their surface is functionalized with an active targeting moiety (a monoclonal antibody against the transferrin receptor). These results, together with the nanoparticle characterization performed here are expected to provide sufficient evidences to end up to clinical trials in the near future. (C) 2015 Elsevier B.V. All rights reserved.

【 授权许可】

Free